Johnson & Johnson 3Q Revenues: $18.5 billion (+5%) 3Q Earnings: $4.7 billion (+59%) YTD Revenues: $56.1 billion (+6%) YTD Earnings: $13.8 billion (+34%) Comments: Worldwide Pharmaceutical sales were $8.3 billion in the quarter, up 18%, with domestic sales up 33%, international sales up 3%, and a negative currency impact of 1%. Sales were driven by new products OLYSIO/SOVRIAD (simeprevir) for chronic hepatitis C; XARELTO (rivaroxaban), an oral anticoagulant; INVOKANA (canagliflozin) for ...